Lifevantage LFVN

Drug Manufacturers - General, Healthcare

$5.86

−2.01%

Market cap: $73.4M
PE: 14.7×; 10y median 19.6×
Forward PE: n/m; not a meaningful number
Price to sales: 0.4×
EV/EBIT: 9.6×
Revenue, 12 months: $182.6M; −20% on a year ago
Net margin: 2.8%
Free cash flow yield: 9.1%

Lifevantage trades at 14.7× trailing earnings, cheaper than 70% of the last ten years. Revenue was $182.6M over the last twelve months, down 20% on a year earlier with a 3% net margin.

Charts

Financials

Income statement for LFVN, by quarter
Income statement	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26
	$51.4M−1%	$51.6M−4%	$48.2M−10%	$48.9M−10%	$47.2M−8%	$67.8M+31%	$58.4M+21%	$55.1M+13%	$47.6M+1%	$48.9M−28%	$43.7M−25%	$42.4M−23%
Cost of revenue	$10.2M+2%	$11.1M−6%	$10.2M−4%	$10M−10%	$9.5M−7%	$13.2M+19%	$11.1M+9%	$11.1M+10%	$9.7M+3%	$12.7M−4%	$9.2M−18%	$9.3M−16%
Gross profit	$41.2M−2%	$40.6M−3%	$38.1M−12%	$38.9M−10%	$37.7M−8%	$54.6M+35%	$47.3M+24%	$44M+13%	$37.8M+0%	$36.2M−34%	$34.5M−27%	$33M−25%
R&D	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
SG&A	$18M+7%	$20.1M+3%	$16.4M−7%	$14M−18%	$14.8M−17%	$18.6M−7%	$17.1M+4%	$18.7M+33%	$14.9M+0%	$15.8M−15%	$13.9M−19%	$13.9M−26%
	$749K−42%	−$1.3M+2%	$1.9M+21%	$2.9M+12%	$2.6M+243%	$3.4M	$4.1M+110%	$2.1M−26%	$2.3M−12%	$487K−86%	$1.7M−59%	$1.7M−22%
Interest expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pre-tax income	$829K−3%	−$1.1M+3%	$1.9M+15%	$2.7M+6%	$2.6M+211%	$3.1M	$4.2M+118%	$2.4M−12%	$2.2M−13%	$473K−85%	$1.7M−60%	$1.7M−29%
	$200K−17%	−$456K+2582%	$262K−59%	$1.4M+138%	$752K+276%	$539K	$710K+171%	$437K−69%	$86K−89%	$197K−64%	$294K−59%	$417K−5%
Net income	$629K+3%	−$656K−38%	$1.7M+62%	$1.3M−34%	$1.8M+190%	$2.5M	$3.5M+109%	$2M+50%	$2.2M+18%	$276K−89%	$1.4M−61%	$1.3M−35%
	$0.05+0%	−$0.05−38%	$0.13+63%	$0.10−38%	$0.14+180%	$0.19	$0.26+100%	$0.15+50%	$0.17+21%	$0.02−90%	$0.11−58%	$0.10−33%
	13.1M+5%	12.6M+1%	13M+2%	12.9M+3%	12.8M−2%	13.2M+5%	13.3M+2%	13M+1%	12.9M+1%	12.7M−3%	12.7M−5%	12.5M−4%

Income tax: Q1 FY11: 6 months less the 3 months printed beside them.

EPS, diluted: 6 periods, Q4 FY11 to Q4 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: 3 periods, Q4 FY11 to Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 13 periods, Q4 FY12 to Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Lifevantage's size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
LFVNLifevantage	$73.4M	14.7×	19.6×	0.4×	−20%	2.8%
SPROSpero Therapeutics	$64.6M	10.1×	9.5×	1.4×	−3%	15.7%
ATNMActinium Pharmaceuticals	$47.8M	4.2×	3.1×	n/m	n/m	n/m
NATRNatures Sunshine Products	$213.8M	12.0×	20.6×	0.4×	+7%	3.7%
ARVNArvinas	$477.3M	45.6×	52.3×	1.5×	−15%	2.9%
PBYIPuma Biotechnology	$568.9M	21.2×	12.3×	2.5×	−3%	11.6%
IRWDIronwood Pharmaceuticals	$571.7M	4.5×	14.9×	1.5×	+26%	33.4%
ZVRAZevra Therapeutics	$582.6M	10.5×	12.3×	4.3×	+119%	42.8%
CRMDCorMedix	$611.9M	3.7×	4.0×	1.3×	+281%	40.5%
Peer median	$523.1M	10.3×	12.3×	1.5×	+7%	15.7%